What question did this study set out to answer?

To explore the effectiveness of Lorlatinib as a treatment for relapsed pediatric ALK+ Anaplastic Large Cell Lymphoma.

June 13, 2026

Successful Treatment of Relapsed Pediatric Central Nervous System ALK+ Anaplastic Large Cell Lymphoma With Lorlatinib Monotherapy

CVCourtney M. VaughnUniversity of North Carolina at Chapel Hill CSCatherine Evers SmithWashington University in St. Louis LSLaura G. Schuettpelz

Puntos clave

To explore the effectiveness of Lorlatinib as a treatment for relapsed pediatric ALK+ Anaplastic Large Cell Lymphoma.
Reported a case of a pediatric patient with systemic and CNS relapse of ALK+ ALCL.
Administered Lorlatinib as a monotherapy.
Monitored for treatment outcomes and remission.
The patient achieved complete remission following Lorlatinib treatment.
Supports the potential for Lorlatinib in treating CNS relapses of ALK+ ALCL.
Suggests inclusion of newer ALK inhibitors in initial therapy for pediatric patients.

Resumen

BACKGROUND: Pediatric Anaplastic Lymphoma Kinase-driven (ALK+) Anaplastic Large Cell Lymphoma (ALCL) offers an exciting opportunity for targeted therapy. Standard frontline chemotherapy for ALK+ ALCL is associated with severe toxicities; ALK inhibition may provide an opportunity to decrease this toxicity and improve relapse outcomes. OBSERVATION: We present a patient with both a systemic and CNS relapse of her ALK+ ALCL who achieved complete remission with ALK inhibitor monotherapy. CONCLUSION: This case supports studying the inclusion of newer ALK inhibitors in upfront therapy for pediatric ALK+ ALCL and supports the use of Lorlatinib to treat CNS relapse of ALK+ ALCL.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo